ArticleFrontiers in medicine2026
Predictive value of postoperative C-reactive protein-to-albumin ratio for severe complications following radical gastrectomy in gastric cancer patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To assess the prognostic significance of the C-reactive protein-to-albumin ratio (CAR) measured on the third postoperative day (POD 3) for risk stratification of severe complications after radical gastrectomy in gastric cancer (GC) patients. Methods: This retrospective analysis examined clinical data from 200 GC patients who underwent radical gastrectomy between January 2023 and December 2024. The patients were divided into a severe complication group (Clavien-Dindo grade ≥III, Results: On POD 3, the complication group exhibited significantly lower ALB levels as well as higher CRP and CAR levels relative to the control group ( Conclusion: The CAR on postoperative day 3 may serve as an accessible biomarker associated with severe complications after radical gastrectomy in GC patients. However, given the limited number of severe events and the lack of internal or external validation, its discriminatory performance and clinical applicability should be interpreted cautiously and require confirmation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.